Novavax RSV F vaccine trial for women shows promise

Courtesy of
A recent clinical trial of Novavax, Inc.'s RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) involving women between the ages of 18 and 35 years old found that the vaccine improved the body's immune response. 

The randomized, blind, placebo-controlled Phase 2 clinical trial determined the safety as well as immunogenicity of two doses of the RSV F Vaccine, one with aluminum phosphate adjuvant and the other without. The study involved 330 women who were of childbearing age.

“These data are the foundation for our ongoing RSV F Vaccine development program to protect infants via maternal immunization,” Dr. Gregory Glenn, senior vice president of Research and Development for Novavax, said. “The RSV F Vaccine stimulated high levels of anti-F, PCA and microneutralizing antibodies. Further, our ad hoc analysis via Western Blot, together with our recent data in older adults, provides an additional indication that the vaccine-induced immunity can protect against RSV infections in humans. We look forward to announcing additional data from our trial of the RSV F Vaccine in pregnant women later this quarter, a key milestone in our strategy to develop a vaccine designed to protect infants via maternal immunization.”

Further details are available in the Journal of Infectious Disease.

Organizations in this Story


Want to get notified whenever we write about Novavax ?
Next time we write about Novavax, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.